Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03075527 · OUTCOME

Median Duration of Response (DOR)

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma · Source last updated 2026-07-16

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
80% Confidence Interval
Time frame
The median of treatment duration is 1.91 months with range (0.00 months - 23.46 months).

What was measured

DOR is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (or censored at the date of last disease evaluation).

Analysis population: This analysis dataset is comprised of all patients who had a CR or PR on treatment.

Groups in this outcome

Tremelimumab + Durvalumab

Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Tremelimumab + Durvalumab2

Reported measurements

Source class 1
Values in months · Interval/dispersion: 80% Confidence Interval
GroupValueSpreadLowerUpperComment
Tremelimumab + Durvalumab2.07Not reported2.07NAThe upper bound of the 80% CI for median DOR is NA due to insufficient events.
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        The upper bound of the 80% CI for median DOR is NA due to insufficient events.
        group Id
        OG000
        lower Limit
        2.07
        upper Limit
        NA
        value
        2.07
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    units
    Participants
description
DOR is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (or censored at the date of last disease evaluation).
dispersion Type
80% Confidence Interval
groups
  1. description
    Subjects will receive durvalumab and tremelimumab both via intravenous infusion once per day for every 28 day cycles (+ 7 days). Participants will receive tremelimumab for up to 4 cycles (4 doses). Beginning with cycle 5 day 1, subjects will continue to receive durvalumab alone, until clinical or radiological progression. Tremelimumab: Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack. Durvalumab: Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
    id
    OG000
    title
    Tremelimumab + Durvalumab
param Type
MEDIAN
population Description
This analysis dataset is comprised of all patients who had a CR or PR on treatment.
reporting Status
POSTED
time Frame
The median of treatment duration is 1.91 months with range (0.00 months - 23.46 months).
title
Median Duration of Response (DOR)
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice